8-K: Protagonist Reports Q2 2025 Results, Advances Pipeline

Protagonist Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in its clinical pipeline with NDA filings for icotrokinra and rusfertide on track, alongside a strong cash position.

Summary

• The New Drug Application (NDA) for icotrokinra, for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO), was submitted to the U.S. FDA in July.
• The full data set from the positive Phase 3 VERIFY trial of rusfertide in polycythemia vera (PV) was presented during a plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in June.
• The U.S. NDA filing for rusfertide for the treatment of patients with PV, by partner Takeda Pharmaceuticals, is expected in Q4 2025.
• The ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis is scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7, 2025.
• Cash, cash equivalents, and marketable securities were $673.0 million as of June 30, 2025, which is anticipated to provide a cash runway through at least the end of 2028.
• Net loss for the second quarter of 2025 was $34.8 million, or $0.55 per basic and diluted share, compared to a net loss of $30.6 million, or $0.50 per basic and diluted share, for the second quarter of 2024.
• License and collaboration revenue for the second quarter of 2025 was $5.5 million, an increase from $4.2 million in the second quarter of 2024.
• Research and development expense increased to $37.0 million in Q2 2025 from $33.5 million in Q2 2024, primarily due to new product candidates PN-881 and PN-477.
• General and administrative expense increased to $10.6 million in Q2 2025 from $9.4 million in Q2 2024, mainly due to increases in stock-based compensation and personnel-related expenses.
• PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, was selected as a development candidate for the treatment of obesity.
• Preclinical data on PN-881, an IL-17 oral peptide antagonist, was presented at the Society for Investigative Dermatology (SID) Annual Meeting in May.

Sentiment

Score: 8

Explanation: The company demonstrates strong progress in its clinical pipeline with two major NDA filings on track, a robust cash position extending through 2028, and promising early-stage assets in high-demand therapeutic areas like obesity. While net loss increased, this is primarily due to the absence of a one-time revenue event from the prior year and increased R&D investment, which is typical for a growth-oriented biopharmaceutical company.

Positives

• NDA for icotrokinra submitted to U.S. FDA in July, marking a significant regulatory milestone for the plaque psoriasis treatment.
• Phase 3 VERIFY trial data for rusfertide presented at the prestigious ASCO plenary session, indicating strong clinical results for polycythemia vera.
• U.S. NDA filing for rusfertide remains on track for Q4 2025, signaling continued progress towards commercialization.
• Strong cash position of $673.0 million as of June 30, 2025, providing a cash runway through at least the end of 2028, which significantly de-risks future operations.
• Advancement of wholly-owned early-stage assets PN-881 and PN-477 into clinical and IND-enabling studies, respectively, expanding the future pipeline.
• Selection of PN-477 as a development candidate for obesity, targeting a large and growing market with a potential best-in-class triple agonist.
• Positive top-line results from the Phase 2b ANTHEM trial of icotrokinra in moderately to severely active ulcerative colitis, indicating broader potential for the asset.
• License and collaboration revenue increased to $5.5 million in Q2 2025 from $4.2 million in Q2 2024, reflecting ongoing development services under the Takeda collaboration.

Negatives

• Net loss increased to $34.8 million in Q2 2025 from $30.6 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, was $46.4 million, a significant shift from net income of $176.7 million for the same period in 2024, primarily due to the absence of a large upfront payment from the Takeda collaboration recognized in the prior year.
• Research and development expense increased due to investments in new product candidates, contributing to the higher net loss.
• General and administrative expense increased, driven by higher stock-based compensation and personnel-related costs.

Risks

• Ability to develop and commercialize product candidates.
• Ability to earn milestone payments under collaboration agreements with Janssen and Takeda.
• Ability to use and expand programs to build a pipeline of product candidates.
• Ability to obtain and maintain regulatory approval of product candidates.
• Ability to operate in a competitive industry and compete successfully against competitors that have greater resources.
• Ability to obtain and adequately protect intellectual property rights for product candidates.

Future Outlook

The company anticipates filing the U.S. NDA for rusfertide in Q4 2025. They also plan to advance wholly-owned early-stage assets PN-881 into clinical studies and PN-477 into IND-enabling studies. The cash runway is projected to extend through at least the end of 2028.

Management Comments

• "Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month." Dinesh V. Patel, Ph.D., President and CEO.
• "Over the coming months, we look forward to the NDA filing of rusfertide for polycythemia vera, and advancing our wholly owned early-stage assets PN-881 and PN-477 into clinical and IND-enabling studies respectively." Dinesh V. Patel, Ph.D., President and CEO.

Industry Context

The company operates in the biopharmaceutical sector, focusing on discovery through late-stage development of novel peptide therapeutics. The advancement of icotrokinra and rusfertide towards NDA filings positions them as potential new treatments in the psoriasis and polycythemia vera markets, respectively. The entry into the obesity market with PN-477 aligns with a significant and growing industry trend towards GLP-1 based therapies, indicating strategic diversification into high-demand areas.

Comparison to Industry Standards

• The presentation of rusfertide Phase 3 VERIFY trial data at the ASCO Plenary Session is a prestigious recognition, indicating strong clinical results comparable to other leading oncology drug developments.
• Icotrokinra's NDA filing for psoriasis, as an oral IL-23 receptor antagonist, positions it against established and emerging injectable therapies in the dermatology space, such as other IL-23 inhibitors (e.g., Skyrizi by AbbVie, Tremfya by Johnson & Johnson) and IL-17 inhibitors (e.g., Cosentyx by Novartis, Taltz by Eli Lilly, Siliq by Bausch Health). Its oral peptide nature could offer a competitive advantage in patient convenience.
• The development of PN-477, a GLP-1, GIP, GCG triple agonist, places Protagonist in a highly competitive and rapidly expanding market dominated by companies like Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro). Its potential for both oral and subcutaneous administration could differentiate it within this competitive landscape.
• PN-881, an oral IL-17 peptide antagonist, aims to compete with existing injectable IL-17 inhibitors like bimekizumab (Bimzelx by UCB) and secukinumab (Cosentyx by Novartis), with preclinical data suggesting comparable or superior in vitro potency.

Stakeholder Impact

• Shareholders: Positive impact due to significant pipeline progress (NDA filings), strong cash runway, and expansion into new therapeutic areas, potentially increasing long-term value. Increased net loss in the short term is expected for a development-stage company.
• Patients: Potential for new treatment options for plaque psoriasis (icotrokinra) and polycythemia vera (rusfertide), as well as future therapies for ulcerative colitis and obesity.
• Employees: Continued investment in R&D and pipeline expansion suggests stable to growing employment opportunities.
• Partners (Johnson & Johnson, Takeda Pharmaceuticals): Continued collaboration and progress on licensed assets, potentially leading to future milestone payments and commercial success.

Next Steps

• Oral presentation of ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis at the 33rd United European Gastroenterology Week (UEGW) on October 7, 2025.
• U.S. NDA filing for rusfertide for polycythemia vera by partner Takeda Pharmaceuticals expected in Q4 2025.
• Advancing wholly-owned early-stage asset PN-881 into clinical studies.
• Advancing wholly-owned early-stage asset PN-477 into IND-enabling studies.

Key Dates

Recommendation

The company has achieved critical milestones with the NDA submission for icotrokinra and the anticipated Q4 2025 NDA filing for rusfertide, both representing significant value inflection points. The strong cash position provides a long runway, mitigating near-term financing risks. Furthermore, the advancement of promising early-stage assets like PN-477 into the high-growth obesity market demonstrates strategic foresight and diversification. Despite current net losses, these are typical for a biopharmaceutical company in late-stage development and are outweighed by the substantial progress towards commercialization and pipeline expansion.

Keywords

Protagonist Therapeutics, PTGX, SEC filing, 8-K, Q2 2025, financial results, corporate update, icotrokinra, JNJ-2113, plaque psoriasis, PsO, NDA filing, FDA, rusfertide, polycythemia vera, PV, ASCO, Takeda Pharmaceuticals, ANTHEM trial, ulcerative colitis, UEGW, PN-881, IL-17 antagonist, PN-477, GLP-1, GIP, GCG, obesity, biopharmaceutical, clinical development, drug discovery, cash runway